HC Wainwright Issues Pessimistic Forecast for Tyra Biosciences (NASDAQ:TYRA) Stock Price

Tyra Biosciences (NASDAQ:TYRA) had its target price lowered by analysts at HC Wainwright from $32.00 to $30.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 88.21% from the stock’s current price.

TYRA has been the topic of a number of other reports. Wedbush reiterated an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th. Piper Sandler began coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They issued an “overweight” rating and a $33.00 price target on the stock. Oppenheimer lifted their price objective on Tyra Biosciences from $25.00 to $33.00 and gave the company an “outperform” rating in a research note on Thursday, September 19th. Finally, Bank of America upgraded Tyra Biosciences from a “neutral” rating to a “buy” rating and upped their target price for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Tyra Biosciences currently has an average rating of “Buy” and a consensus price target of $31.00.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $15.94 on Monday. Tyra Biosciences has a fifty-two week low of $10.60 and a fifty-two week high of $29.60. The business has a 50-day moving average of $21.62 and a 200 day moving average of $20.01. The firm has a market cap of $841.73 million, a P/E ratio of -9.90 and a beta of 1.08.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Thursday, November 7th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). As a group, research analysts predict that Tyra Biosciences will post -1.53 earnings per share for the current fiscal year.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 27,493 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $16.56, for a total value of $455,284.08. Following the completion of the sale, the director now owns 458,506 shares in the company, valued at $7,592,859.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Tyra Biosciences news, CEO Todd Harris sold 10,092 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $24.13, for a total value of $243,519.96. Following the transaction, the chief executive officer now owns 1,479,528 shares in the company, valued at approximately $35,701,010.64. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Nina S. Kjellson sold 27,493 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $16.56, for a total value of $455,284.08. Following the transaction, the director now directly owns 458,506 shares of the company’s stock, valued at $7,592,859.36. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,050 shares of company stock valued at $2,235,492. Insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers increased its position in Tyra Biosciences by 12.3% during the 2nd quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after purchasing an additional 2,574 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Tyra Biosciences by 2.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 173,737 shares of the company’s stock worth $4,085,000 after buying an additional 3,792 shares during the period. Oppenheimer & Co. Inc. boosted its position in Tyra Biosciences by 9.0% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 76,806 shares of the company’s stock valued at $1,806,000 after acquiring an additional 6,318 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Tyra Biosciences by 5.9% during the 3rd quarter. Jennison Associates LLC now owns 158,187 shares of the company’s stock worth $3,719,000 after acquiring an additional 8,837 shares during the period. Finally, Valence8 US LP bought a new position in shares of Tyra Biosciences in the 3rd quarter worth approximately $310,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.